1. Recent treatment progress of triple negative breast cancer
- Author
-
Lu Hui-Meng, Gong Zi-Qian, Yang Chang-Qing, Zhao Shi-Qi, Zhang Chen-Yan, Zhao Gang, Liu Jie, Yin Dachuan, Zhou Ren-Bin, Xu Ran, and Zhu Kun
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Side effect ,business.industry ,medicine.medical_treatment ,Biophysics ,Estrogen receptor ,Triple Negative Breast Neoplasms ,Disease ,medicine.disease ,Prognosis ,Metastasis ,Breast cancer ,Internal medicine ,Progesterone receptor ,medicine ,Humans ,Neoplasm Metastasis ,business ,Molecular Biology ,Triple-negative breast cancer ,Signal Transduction - Abstract
Breast cancer (BC) is a serious worldwide disease that threatens women's health. Particularly, the morbidity of triple-negative breast cancer (TNBC) is higher than that of other BC types due to its high molecular heterogeneity, metastatic potential and poor prognosis. TNBC lacks of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), so there are still no effective treatment methods for TNBC. Here, we reviewed the classification of TNBC, its molecular mechanisms of pathogenesis, treatment methods and prognosis. Finding effective targets is critical for the treatment of TNBC. Also, refining the classification of TNBC is benefited to choose the treatment of TNBC, because the sensitivity of chemotherapy is different in different TNBC. Some new treatment methods have been proposed in recent years, such as nutritional therapy and noncoding RNA treatment methods. There are some disadvantages, such as the side effect on normal cells after nutrient deprivation, low specificity and instability of noncoding RNA. More studies are necessary to improve the treatment of TNBC.
- Published
- 2019